Hypertension the 'Missed Modifiable Risk Factor' for Diabetic Neuropathy: a Systematic Review

Curr Probl Cardiol. 2023 Apr;48(4):101581. doi: 10.1016/j.cpcardiol.2022.101581. Epub 2022 Dec 28.

Abstract

Diabetes and hypertension stand as the major non-infectious diseases affecting 34.2 million and 1.28 billion people respectively. The literature on the impact of diabetes on hypertension and vice versa is evolving. The major objectives of this review were to compile the evolving literature establishing the role of hypertension in diabetic neuropathy, derive the exact mechanisms for its pathogenesis, and describe evidence-based precise individualized management of diabetic neuropathy in patients having diabetes complicated by hypertension. A systematic review was conducted by searching databases of PubMed, Embase, and Scopus covering the literature from inception to 2022. We included all observational and experimental studies, including both human and animal studies looking into the correlation between diabetic neuropathy and hypertension. Hypertension poses to be the leading modifiable risk factor for the development of diabetic neuropathy, especially distal symmetrical polyneuropathy, producing abnormal nerve conduction parameters and increased vibration perception threshold in patients with diabetes mellitus. Thus, we advocate that good glycemic control in patients with diabetes needs to be supported with strict blood pressure control for preventing and delaying the onset of diabetic neuropathy.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Blood Pressure
  • Diabetes Mellitus, Type 2* / complications
  • Diabetic Neuropathies* / etiology
  • Diabetic Neuropathies* / prevention & control
  • Humans
  • Hypertension*
  • Perception
  • Risk Factors